Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Physician, researcher, leader in fight against HIV in India and worldwide for three decades is mourned globally Dr. Suniti Solomon was a professor of microbiology in […]
The United States plans to place 360,000 multidrug-resistant tuberculosis patients globally on treatment over the next five years, as part of a national tuberculosis action plan […]
Children, people with HIV, pregnant women and others underserved by TB drug development present ethical imperative, opportunities for global disease approaches, authors say
Populations with needs that can and do affect the impacts of tuberculosis treatments are among the most vulnerable to the disease, make up significant proportions of […]
The Senate State and Foreign Operations subcommittee of the Appropriations Committee followed the House’s example this week and proposed flat funding for most global health programs […]